mAb_name,category,arm,VH_sequence,VL_sequence,CDR_H1,CDR_H2,CDR_H3,CDR_L1,CDR_L2,CDR_L3,target_epitope,predicted_Kd_nM,ADC_score
Trastuzumab,Reference,Single,EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,GFNIKDTYIH,RIYPTNGYTRYADSVKG,SRWGGDGFYAMDY,RASQDVNTAVA,SASFLYS,QQHYTTPPT,HER2 Domain IV (557-603),5.0,8.8
Pertuzumab,Reference,Single,EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDTTFYDYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK,GFTFSDSWIH,WISPYGGSTYYADSVKG,DTTFYDYYAMDY,KASQDVSIGVA,SASYRYT,QQYYIYPYT,HER2 Domain II (266-333),1.0,7.8
Zanidatamab,Reference,Arm1 (Domain IV-like),EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,GFNIKDTYIH,RIYPTNGYTRYADSVKG,SRWGGDGFYAMDY,RASQDVNTAVA,SASFLYS,QQHYTTPPT,HER2 Domain II + Domain IV (Biparatopic),0.5,9.5
Zanidatamab,Reference,Arm2 (Domain II-like),EVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARDTTFYDYYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCKASQDVSIGVAWYQQKPGKAPKLLIYSASYRYTGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYYIYPYTFGQGTKVEIK,GFTFSDSWIH,WISPYGGSTYYADSVKG,DTTFYDYYAMDY,KASQDVSIGVA,SASYRYT,QQYYIYPYT,HER2 Domain II + Domain IV (Biparatopic),0.5,9.5
p95-ESM-001,Pipeline-Predicted,Single,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYWWVRQAPGKGLEWVSINPIWKGSRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARARDPIWKFPDYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGACQPLTFGQGTKVEIK,GYTFTSYW,INPIWKGS,ARDPIWKFPDYAMDY,RASQGISSWLA,AASSLQS,QQGACQPLT,p95-HER2 Juxtamembrane (615-635),0.21,9.0
p95-ESM-002,Pipeline-Predicted (TOP),Single,EVQLVESGGGLVQPGGSLRLSCAASGYTFTDYEWVRQAPGKGLEWVSINPKRGSTRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARARDRKEYWFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISKYLNWYQQKPGKAPKLLIYAASRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFPDEEGTFGQGTKVEIK,GYTFTDYE,INPKRGST,ARDRKEYWFDY,RASQDISKYLN,AASRLQS,QQFPDEEGT,p95-HER2 Juxtamembrane (615-635),0.13,9.0
p95-ESM-003,Pipeline-Predicted,Single,EVQLVESGGGLVQPGGSLRLSCAASGYTFTSYYWVRQAPGKGLEWVSINWWGGSTRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARARCTHSCVDYFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQSVSSSYLAWYQQKPGKAPKLLIYGASSRATGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQDLDKGCTFGQGTKVEIK,GYTFTSYY,INWWGGST,ARCTHSCVDYFDY,RASQSVSSSYLA,GASSRAT,QQDLDKGCT,p95-HER2 Membrane-proximal (640-652),0.33,8.0
p95-ESM-004,Pipeline-Predicted,Single,EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYMWVRQAPGKGLEWVSINMETPGSRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARARMETPIWKFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQMETSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQMPIWFPTFGQGTKVEIK,GYTFTNYM,INMETPGS,ARMETPIWKFDY,RASQMETSWLA,AASSLQS,QQMPIWFPT,p95-HER2 Neo-epitope (611-625),0.20,9.0
p95-Trastuzumab-Biparatopic,Pipeline-Predicted (RECOMMENDED),Arm1 (p95-JM),EVQLVESGGGLVQPGGSLRLSCAASGYTFTDYEWVRQAPGKGLEWVSINPKRGSTRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARARDRKEYWFDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDISKYLNWYQQKPGKAPKLLIYAASRLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQFPDEEGTFGQGTKVEIK,GYTFTDYE,INPKRGST,ARDRKEYWFDY,RASQDISKYLN,AASRLQS,QQFPDEEGT,p95-HER2 JM (615-635) + FL-HER2 Domain IV,0.08,9.5
p95-Trastuzumab-Biparatopic,Pipeline-Predicted (RECOMMENDED),Arm2 (Domain IV),EVQLVESGGGLVQPGGSLRLSCAASGFNIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSS,DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIK,GFNIKDTYIH,RIYPTNGYTRYADSVKG,SRWGGDGFYAMDY,RASQDVNTAVA,SASFLYS,QQHYTTPPT,p95-HER2 JM (615-635) + FL-HER2 Domain IV,0.08,9.5
